Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide in hepatic impairment
NCT06535399Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of golcadomide (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum observed plasma concentration at 44 days, Time of maximum observed plasma concentration at 44 days and 1 more. Started Aug 2024; status: completed.
02
Drugs
golcadomide
Beyond the preview
Go deeper on NCT06535399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535399.